Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of
retinal nonperfusion area. This protective effect would cause the increase of the oxygen
consumption in the diabetic retina. We expect that the current study using the retinal
oximetry would show the protective effects of ranibizumab on the hypoxia in the diabetic
retina. This study is designed to analyze the effects of ranibizumab (Lucentis) to the
retinal oxygen saturation or consumption in eyes with diabetic macular edema.